{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=40&state=Ohio", "query": { "state": "Ohio", "city": "Cincinnati", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 10556, "total_pages": 1056, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=41&state=Ohio&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=39&state=Ohio&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T15:55:34.551Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03626545", "title": "Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 245, "start_date": "2019-01-23", "completion_date": "2021-12-20", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-11-07T15:55:34.551Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03626545" }, { "nct_id": "NCT02783651", "title": "An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Relapsed/Refractory Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Other", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 212, "start_date": "2016-06-30", "completion_date": "2020-03-31", "has_results": false, "last_update_posted_date": "2020-04-27", "last_synced_at": "2026-11-07T15:55:34.551Z", "location_count": 19, "location_summary": "Tucson, Arizona • Duarte, California • Los Angeles, California + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ames", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02783651" }, { "nct_id": "NCT00942331", "title": "Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Prostate Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Stage IV Bladder Urothelial Carcinoma AJCC v7", "Stage IV Prostate Cancer AJCC v7", "Stage IV Renal Pelvis Cancer AJCC v7", "Stage IV Ureter Cancer AJCC v7", "Stage IV Urethral Cancer AJCC v7", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 506, "start_date": "2009-07-15", "completion_date": "2021-06-15", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-11-07T15:55:34.551Z", "location_count": 872, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 529 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00942331" }, { "nct_id": "NCT00280995", "title": "Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia, Familial" ], "interventions": [ { "name": "ISIS 301012", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kastle Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2006-01", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2016-08-03", "last_synced_at": "2026-11-07T15:55:34.551Z", "location_count": 5, "location_summary": "Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00280995" }, { "nct_id": "NCT05010577", "title": "Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Pseudomonas Aeruginosa Infection", "Cystic Fibrosis" ], "interventions": [ { "name": "BX004-A", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BiomX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2022-06-21", "completion_date": "2024-03-10", "has_results": false, "last_update_posted_date": "2025-07-18", "last_synced_at": "2026-11-07T15:55:34.551Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05010577" }, { "nct_id": "NCT01959529", "title": "A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 7637, "start_date": "2013-10-29", "completion_date": "2016-10-16", "has_results": true, "last_update_posted_date": "2019-07-24", "last_synced_at": "2026-11-07T15:55:34.551Z", "location_count": 267, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 209 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01959529" }, { "nct_id": "NCT03022708", "title": "Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Heart Defect, Congenital" ], "interventions": [ { "name": "Xeltis Bioabsorbable Pulmonary Valved Conduit", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Xeltis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 6, "start_date": "2017-05-08", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-07T15:55:34.551Z", "location_count": 7, "location_summary": "Los Angeles, California • Aurora, Colorado • Hollywood, Florida + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03022708" }, { "nct_id": "NCT01012297", "title": "Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Uterine Corpus Sarcoma", "Stage IIIA Uterine Sarcoma", "Stage IIIB Uterine Sarcoma", "Stage IIIC Uterine Sarcoma", "Stage IVA Uterine Sarcoma", "Stage IVB Uterine Sarcoma", "Uterine Corpus Leiomyosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 107, "start_date": "2009-11", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-11-07T15:55:34.551Z", "location_count": 201, "location_summary": "Phoenix, Arizona • Burbank, California • Concord, California + 138 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01012297" }, { "nct_id": "NCT04626635", "title": "A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "REGN7075", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Platinum-based doublet chemotherapy", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Trifluridine-tipiracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 548, "start_date": "2020-12-21", "completion_date": "2027-03-05", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-11-07T15:55:34.551Z", "location_count": 20, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04626635" }, { "nct_id": "NCT04982835", "title": "M6-C Artificial Cervical Disc Two-Level IDE Pivotal Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cervical Disc Degenerative Disorder" ], "interventions": [ { "name": "M6-C Artificial Cervical Disc", "type": "DEVICE" }, { "name": "ACDF", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Orthofix Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 156, "start_date": "2021-07-26", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-11-07T15:55:34.551Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04982835" } ] }